Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
Maryna V. Basalay
Sean M. Davidson
Derek M. Yellon
1.The Hatter Cardiovascular Institute, University College London, London, UK2.The Hatter Cardiovascular Institute, University College London, London, UK3.The Hatter Cardiovascular Institute, University College London, London, UK
摘要：Currently, ischemic stroke remains one of the most costly and devas-tating clinical syndromes, accounting for 9% of all deaths and being the second leading cause of death in the world (Davidson et al., 2018). Approximately 20% of strokes are caused by intracerebral hemorrhage, while the other ~80% are classified as ischemic. With the discovery of thrombolysis, reperfusion therapy became an option for the treatment of ischemic stroke. More recently, endovascular recanalization with mechanical thrombectomy has brought about a paradigm shift in the optimal management of patients with large vessel occlusion. Important-ly, early reperfusion is the only therapy that is proven to limit infarct size in patients with acute ischemic stroke. However, despite a success-ful recanalization being achieved in more than 70% of patients treated with mechanical thrombectomy +/– intravenous tissue recombinant plasminogen activator, functional independence (modified Rankin score 0–2 at 3 months after ischemic stroke) is obtained only in ~45% of cases. This reveals the further need to develop new adjunctive neuro-protective treatment strategies alongside reperfusion therapy.
机标关键词：
论文发表日期：2020-10-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 1852-1854 )